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EXPRESSION OF THE EXTRACELLULAR NUCLEOTIDE
DIPHOSPHOHYDROLASE, NTPDASE2, IS DOWN-REGULATED IN PRIMARY
CHOLANGIOPATHIES. Joahd Toure, Jonathan Dranoff, Dhanpat Jain, Section of
Gastroenterology, Department of Internal Medicine, Yale University, School of
Medicine, New Haven CT.
Portal fibroblasts are newly discovered liver cells that may be of particular importance in
biliary fibrosis. Recent data indicate that portal fibroblasts express NTPDase2, an ectonucleoside triphosphate diphosphohydrolase. Portal fibroblasts exist within the periportal regions of rat livers and express NTPDase2 adjacent to the basolateral side of
intrahepatic bile ducts. Because extracellular nucleotides regulate secretion via activation
of P2Y purinergic receptors, extracellular nucleotide hydrolysis via NTPDase2 makes
NTPDase2 a potential regulator of bile ductular secretion. We propose that NTPDase2
expression may be altered in biliary fibrosis, especially in conditions in which bile duct
epithelia are the target of disease. To test this hypothesis we have contrasted the
distribution of NTPDase2 in normal and diseased liver states. Using confocal
immunofluorescence, we assessed differences in expression of NTPDase2 in liver biopsy
specimens from normal liver, primary biliary cirrhosis (PBC), and hepatitis C (HepC).
We found that NTPDase2 was down regulated in the peri-portal regions of patients with
PBC when compared to normal patients. Hepatitis C, however, showed NTPDase2
staining equal to or nearly equal to that of normal liver. The intermediate filament
vimentin was down regulated in both PBC and Hep C when compared to normal liver.
We conclude that NTPDase2 expression is down regulated in PBC but not Hep C, while
vimentin is down regulated in both disease states when compared to normal liver.
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1
Introduction

Cholangiopathies are disorders characterized by primary damage to biliary epithelia.
Running the spectrum from autoimmune disorders to congenital genetic defects, the
pathophysiology of cholangiopathies involves bile duct cell death and various degrees of
portal fibrosis. (29) Patients are jaundiced and pruritic because of prolonged cholestasis.
They also suffer from fatigue, steatorrhea, and possibly bone pain from resultant
osteoporosis or osteomalacia. While treatment with ursodeoxycholic acid may modestly
slow progression of the disease (36), novel therapies for cholangiopathies are desperately
needed to enhance the health of these patients.

Significant advances have been made in understanding the physiology of ion transport
and bile ductular secretion. Efforts to characterize the ion transport systems of bile duct
epithelia have revealed several intra- membrane ion channels. Chloride is secreted via
cAMP dependent apical CFTR chloride channels and intracellular calcium dependent
apical chloride channels, and the alkalinization of bile occurs through an apical Cl/HCO3- antiport system (2, 12, and 13). Extracellular nucleotides are potent regulators of
bile ductular secretion. This secretion occurs via activation of P2 nucleotide receptors on
the plasma membrane of bile duct cells (8). (See Diagram 1)

The list of P2 receptors includes P2X receptors, which display intrinsic cation channel
properties (8, 19), and P2Y receptors, which are coupled to phospholipase C via Gqproteins (8). There are at least seven receptors of the P2X class and eight from the P2Y
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class (35). Evidence indicates that multiple P2Y receptors subtypes are expressed on
both the apical and basolateral surfaces of rat cholangiocytes (5) and that stimulation of
these nucleotide receptors mediates bile duct secretion. The exposure of P2Y receptor
expressing bile duct epithelial cells to ATP causes intracellular calcium and inositol
phosphates to rise (1). Cultured polarized rat bile duct cells were noted to establish a
basolateral to apical Cl- transport current to varying degrees when exposed to different
nucleotides and nucleosides (1). Furthermore, CFTR Cl- conductance is activated in
polarized T84 epithelia when exposed to extracellular ATP (11). Taken together these
data suggest that extracellular nucleotides can induce chloride secretion from bile duct
epithelia, likely via calcium dependent chloride channels and CFTR channels. However,
the association between rises in intracellular calcium and chloride secretion are not
entirely understood.

The presence of nucleotides in bile and their ability to induce biliary secretion suggest a
primary role for extracellular nucleotides as paracrine and or autocrine signals in the
liver. ATP and other nucleotides are found in bile at concentrations sufficient for P2Y
receptor activation (17). ATP released from hypotonic bile duct cells causes chloride
secretion from those same cells and is inhibited by the P2Y receptor blocker suramin as
well as the nucleotide hydrolyzing enzyme apyrase (3, 18). Mechanical stimulation of a
single hepatocyte causes not only an increase in the intracellular calcium of that
particular hepatocyte, but also in nearby hepatocytes and bile duct epithelium. Preperfusion of ATP suppressed this increase, as did apyrase (an ATP/ADPase) and suramin
(a P2 receptor antagonist) (20). Taken together, this information implies that ATP may
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be released by bile duct cells and hepatocytes when stimulated by hypotonicity or
mechanical stress. Moreover, this provides direct evidence that ATP serves as a
paracrine and or autocrine signal for hepatocytes and bile duct cells, activating P2Y
receptors and causing a number of down stream effects in the surrounding cells.

Extracellular nucleotides may also play a role in cell proliferation in several cell types.
There have been studies which demonstrate that proliferation is regulated through P2Y
receptors. (30, 31) The downstream targets of P2Y receptor activation involved in
proliferation are less clearly understood. However, these studies directly implicate
certain signaling cascades. P2Y receptor activation leads to PKC activation (32) as well
as an increase in intracellular calcium. Both of PKC and intracellular calcium are second
messengers known for regulating cell growth and proliferation (4). Protein kinase A
(PKA) (33) and the mitogen-activated protein kinase (MAP kinase) (30, 31) signaling
cascades have also been implicated. (See Diagram 1)

The many receptor sub-types and their different selectivities for different nucleotides
make it difficult to determine the individual and aggregate effects that receptor activation
has on the function of bile duct epithelia. Additionally, the bile duct cell is polarized and
its response to P2Y receptor activation differs depending on which side of the cell
activation takes place. Chloride secretion (5), bicarbonate secretion (5), the increase of
intracellular calcium (5), ATP release (3), and rate of nucleotide degradation (3), all differ
according to whether the site of activation is apical or basolateral.
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While a single nucleotide degradation pathway is thought to exist in the apical
compartment, multiple degradation pathways may exist in the basolateral compartment
(3). Recent evidence has revealed NTPDase2, an enzyme which hydrolyzes extracellular
nucleotides, as a possible candidate for basolateral nucleotide degradation. Extracellular
nucleotide degradation is accomplished by several different ecto-nucleotidases. Ectonucleotidases are plasma membrane-bound enzymes which hydrolyze phosphate groups
from nucleotide triphosphates. Nucleotide monophosphates and nucleotide diphosphates
result from hydrolysis. Nucleotide monophosphates do not have the ability to activate
P2Y receptors, while nucleotide diphosphates and nucleotide triphosphates do.
Therefore, ecto-nucleotidases can regulate the activation of P2Y receptors. There are
several different ecto-nucleotidases, named nucleotide diphosphohydrolases (NTPDase),
two of which are mentioned below.

NTPDase2, also known as CD39L1, is expressed in epithelial tissues (19, 20).
NTPDase1, also known as CD39, is expressed in endothelial cells and is believed to help
regulate platelet aggregation (25). NTPDase2 is present in a membranous compartment
of portal fibroblasts surrounding intrahepatic bile ducts. Portal fibroblasts also express
the intermediate filament vimentin, as well as procollagen I (6). It is known that only
non-hydrolysable forms of ATP significantly activate basolateral P2Y receptors. (5)
Therefore, NTPDase2 may mediate activation of basolateral P2Y receptors via nucleotide
hydrolysis. (See Diagram 1) NTPDase’s presence in portal fibroblasts adjacent to the
basolateral surface of hepatic bile ducts makes it perfectly situated to perform in this
function. NTPDase2 is therefore potentially able to regulate the function of bile duct
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epithelia through regulation of basolateral P2Y receptors on bile duct epithelia. Hence,
bile ductular secretion as well as bile duct proliferation may be subject to regulation via
hydrolysis of nucleotides by NTPDase2 of portal fibroblasts.
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Diagram 1: Expression of NTPDase2 in portal fibroblasts and the degradation of
extracellular nucleotides. The above diagram shows bile duct cells with P2Y receptors
(pink) on the basolateral surface. The portal fibroblast exists on the basolateral side and
expresses the enzyme NTPDase2 (green) which degrades extracellular nucleotides. P2Y
receptor activation with nucleotide triphosphates results in PLC-y activation, increases in
intracellular calcium, cAMP, and IP3 . Increases in these second messengers leads to
chloride and bicarbonate secretion across the apical membrane via ion channels, as well
as the transduction of signals which may play a role in proliferation.
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Statement of Purpose, Hypothesis

The review above indicates that extracellular nucleotides play a part in the regulation of
biliary secretion via activation of P2Y receptors on the apical surfa ce of bile duct cells.
Moreover, given that basolateral P2Y receptor activation is limited by nucleotide
hydrolysis and also that NTPDase2 is expressed in portal fibroblasts along the basolateral
surface, NTPDase2 is particularly situated to effect P2Y activation, biliary secretion and
bile duct cell proliferation. We therefore question whether NTPDase2 expression is
altered in cholangiopathies. Ductopenia and decreased biliary secretion are characteristic
of cholangiopathies. In response, NTPDase2 expression may be decreased in order to
reduce the hydrolysis of P2Y receptor agonists needed to stimulate biliary secretion and
bile duct cell proliferation. We hypothesize that NTPDase2 will be specifically downregulated in primary biliary cirrhosis, but not other forms of liver cirrhosis. We believe
that the down regulation of NTPDase2 and subsequent activation of the basolateral P2Y
receptors is important in countering the biliary stasis and ductopenia of cholangiopathies.
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Methods

Fluorescence Immunohistochemistry
To determine the cellular and subcellular distribution of NTPDase2, sections of normal
and diseased human liver were labeled with antibodies to NTPDase2. Rabbit polyclonal
antibody BZ3K2 was raised against human NTPDase2. (34)

Fluorescence immunohistochemistry was performed on approximately micrometer thick
sections of human liver. Liver sections included normal liver, primary biliary cirrhosis,
primary sclerosing cholangitis, and hepatitis C. Tissue was deparafinized in 100% xylene
and then serially washed in 100% ethanol and water. After further washing in a 1x PBS
+ 1% bovine serum albumin (BSA) solution the tissue was fixed in 3.7% formaldehyde at
-20 degrees Celsius for 10 minutes. The sections were then serially washed in 1x PBS +
1% BSA solution. Samples were then triple labeled by incubating with rabbit anti- human
NTPDase2 antibody diluted 1:50 in 1x PBS, anti-human vimentin-Cy5 conjugated
(diluted 1:50 in PBS), and rhodamine- phalloidin conjugated (diluted 1:40 in PBS.) The
samples were incubated with the above antibodies for 1hr at 37 degrees Celsius. Samples
were then serially washed in 1x PBS + 1% BSA and incubated with Alexa 488conjugated anti-rabbit secondary antibodies for 45 minutes at 37 degrees Celsius.

Confocal Imaging
Specimens were examined using a Zeiss LSM 510 confocal imaging system (Zeiss,
Oberkochen, Germany) equipped with both a krypton/argon and helium/neon laser at
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x200 magnification. Specimens were serially excited at 488nm and observed at more
than 515nm to detect Alexa 488, and then excited at 568nm and observed at more than
585nm to detect rhodamine, and then excited at 610nm and observed at more than 650nm
to detect Cy5 fluorescence.

Data Analysis
The threshold immunofluorescence settings were determined. All specimens were
viewed under identical settings on the zeiss imaging system to ensure accurate
interpretation of relative immunofluorescence. Specimens were examined by twenty two
blinded observers for scoring. Each Blinded observerr viewed visua l fields (two normals,
two primary biliary cirrhosis, and two hepatitis C) and recorded their interpretation of
green fluorescent intensity on a scale from one to ten. Visual fields which imaged portal
areas or bile ducts were chosen. A rated intensity for an individual field rated by a
blinded observer was counted as a single observation. With 22 observers and two visual
fields for each tissue diagnosis, 44 observations were for comparison in a student’s t-test.
The images of stained livers were un-blinded after observation and the recorded
observational fluorescent intensity was averaged. Means were calculated and a student’s
t-test was used to determine any statistical significance between the means.
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Results
Figure 1: NTPDase2 is expressed in the regions surrounding intrahepatic bile ducts as
well as the along the sinusoidal surface of hepatocytes in normal liver.

Figure 1: The portal area of normal human liver. NTPDase2 is expressed in the regions
surrounding intrahepatic bile ducts. For these experiments, NTPDase2 fluorescence is
green, and red fluorescence indicates vimentin. Five micrometer width human liver
sections were stained with fluorescent antibodies described previously in the methods
section. Using confocal immunofluorescence microscopy we see that green fluorescence
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is noticeably elevated in the portal areas of normal liver. (Figure 1a) However,
immediately surrounding the bile ducts, green fluorescence appears slightly less intense
than in other areas of the portal region. Red immunofluorescence indicates staining with
anti-vimentin antibody shown in figure 2a. Vimentin (an intermediate filament expressed
in portal fibroblasts) fluoresces strongly in the portal areas as well, though not as strongly
as NTPDase2. Co localization of NTPDase2 and vimentin within the portal regions of
normal liver is shown in figure 3. The combination of green and red fluorescence yields
an orange-yellow color in this portal region. The parenchyma of normal tissue shows
modest fluorescence of NTPDase2 along the sinusoidal surface of parenchymal
hepatocytes in normal liver. This expression of NTPDase2 in the portal regions and its
co localization with vimentin is consistent with what has been previously reported by our
lab in Sprauge Dawley rats. The expression of NTPDase2 along the sinusoidal surface of
hepatocytes is a new finding.

Figure 2: Primary Biliary Cirrhosis. NTPDase2 is down regulated in the areas
surrounding intrahepatic bile ducts in primary biliary cirrhosis.
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Figure 2: Primary Biliary Cirrhosis. The
expression of NTPDase2 is significantly decreased as indicated by the remarkably weak
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intensity of green fluorescence in primary biliary cirrhosis. (Figure 2a.) Unlike in normal
tissue, the areas around the bile ducts, labeled BD in figure 2c, do not have show
appreciable NTPDase2 expression. The intensity of red fluorescence is also decreased in
primary biliary cirrhosis, indicating decreased vimentin expression. Figure 2c shows
both green and red fluorescence in primary biliary cirrhosis. The figure demonstrates
both the low level intensity of fluorescence as well as a lack of co localization of the two
fluorescent antibodies. Figure 2d is a high powered slide showing the marginal
NTPDase2 expression next to intrahepatic bile ducts. Figure 2e. and 2f. indicate the
intensity level of vimentin and rhodamine fluorescence respectively. Figure 2e shows
that vimentin did not fluoresce strongly above the background in the areas around bile
ducts in primary biliary cirrhosis. Figure 2f shows the diffuse staining pattern of
rhodamine stained diffusely. Figure 2g. shows all three fluorescent stains. The only
areas with co localization appeared between bile duct cells, labeled Fl in figures 2d.
through 2g.
Figure 3: The NTPDase2 threshold for normal liver is significantly lower for that of
primary biliary cirrhosis.
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Table 1: Threshold settings for normal liver and Primary Biliary Cirrhosis.
Parameter

Normal

Primary Biliary Cirrhosis

Pin Hole Airy Units:

1.89

3.18

Detector Gain:

844

1185

Amplifier Offset:

-0.015

0.1

Amplifier gain:

1.0

1.0

Figure 3: For these experiments the zeiss imaging system was used to determine the
threshold lowest settings necessary for visualization of intense green fluorescence above
the background. Figure 3a shows the characteristic NTPDase2 staining around
intrahepatic bile ducts in normal liver. The settings for required for visualization in
normal liver were much lower than those required for visualization in primary biliary
cirrhosis. (Compare parameter settings in Table 1) The pinhole size required for
threshold in normal liver was nearly half that required for primary biliary cirrhosis
threshold. Figures 3c. and 3d. show dual staining with NTPDase2 and vimentin for the
images seen in 3a. and 3b. respectively. This data indicates that threshold for detection of
NTPDase2 is considerably lower in normal liver than in primary biliary cirrhosis.
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Figure 4: Hepatitis C virus infected liver. The level of NTPDase2 fluorescence in
cirrhotic hep C liver is near that of normal liver.

Figure 4: Hepatitis C expresses NTPDase2 with intensity similar to that of normal liver.
The bridging fibrosis typical of chronic Hepatitis C virus infection is shown in figure 4a.
This figure also shows the considerable green fluorescence along the bridges of fibrotic
tissue. The parenchymal nodules do not fluoresce NTPDase2 to an appreciable extent.
(Figure 4a.) Figure 4b. shows the high level of NTPDase2 fluorescent intensity around
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bile ducts within a fibrotic segment. However,
there was a milder increase in red fluorescence around bile ducts in hepatitis C, however,
not nearly as strong as NTPDase2. (Figure 4c.) Rhodamine, stained diffusely in hepatitis
C infected liver and the three stains are visualized together in figure 4d.

Figure 5. Average intensity of fluorescence between normal liver, primary biliary
cirrhosis and, hepatitis c infected liver.
Average observer determined NTPDase2 fluorescent
intensity between normal liver, PBC, and HCV
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Twenty two blind observers viewed six visual fields (two of each liver tissue) and
recorded their interpretation of green fluorescent intensity on a scale from one to ten.
Visual fields which clearly showed either portal triads or bile ducts were used. The
images of stained livers were un-blinded after observation and the recorded observational
fluorescent intensity was averaged. The average observed green fluorescent intensity was
highest for normal liver (8.41). The observed fluorescence was nearly as high for
hepatitis C (7.48), but significantly lower for primary biliary cirrhosis (1.25). To
determine if a difference in average intensity between liver tissues existed, we performed
a student’s t-test. An alpha of 0.05 was used for calculation of two tail p- values. The
data revealed a two-tail p-value of 2.74 E-37 when comparing the average fluorescence
observed between normal liver and primary biliary cirrhosis. A two-tail p-value of 1.13
E-5 was calculated when comparing average fluorescence observed between normal liver
and hepatitis C. Both values indicate that the difference in averages observed were
statistically significant.
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Our stains of normal liver tissue yielded results which are consistent with previous data
collected from rodent livers. In these experiments increased NTPDase2 staining was
seen in the peri-portal area (Figure 1a.). The distribution of vimentin paralleled that of
NTPDase2. (Figure 1b.) Vimentin, like NTPDase2 stained heavily in the portal areas of
normal liver tissue. When vimentin and NTPDase2 were viewed together, green and red
fluorescence overlapped in the portal area yielding a yellow-orange fluorescence.
Rhodamine phalloidin, a marker for the intracytoskeletal protein actin, (pseudocolored
blue) stained in those areas that did not stain for NTPDase2. (Data not shown) The co
localization of NTPDase2 and vimentin is in agreement with our previous
immunohistochemistry data. (4) It is also in agreement with the recent discovery that
portal fibroblasts express vimentin and NTPDase2 but not actin. (6) These data suggest
that like in rats, human liver also contain portal fibroblasts in the peri-portal regions and
express NTPDase2 as well as vimentin but not actin.

However, our stains also revealed that the parenchyma of human liver tissue expresses
NTPDase2 in the sinusoids. NTPDase2 expression was noted in along the sinusoidal
surface of hepatocytes in normal liver. (Figure 1d.) However, the sinusoidal green
fluorescence in normal liver was not as intense as the fluorescence seen in the portal
areas. This finding was not previously noted in sprauge dawley rats.

While NTPDase2 clearly showed increased fluorescence, vimentin did not have a specific
staining pattern within the parenchyma of normal tissue. (Data not shown) Unlike the
portal areas, the distribution of vimentin in the parenchyma did not parallel that of
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NTPDase2. Rhodamine did not have an appreciable distribution in the parenchyma.
(Data not shown)

In liver with primary biliary cirrhosis, the intensity of NTPDase2 fluorescence was
remarkably lower than that seen in normal liver. (Figure 2a.) The areas surrounding the
bile ducts of primary biliary cirrhosis showed no increase in NTPDase2 staining. The
parenchyma did not show increased NTPDase2 staining either. (Data not shown) High
power images focusing on the areas immediately adjacent to bile ducts in primary biliary
cirrhosis demonstrate the conspicuously absence of high intensity green fluorescence.
(Figure 2d.) The tissue samples of primary biliary cirrhosis were observed under same the
parameters used for normal tissue. Hence, NTPDase2 expression is clearly decreased in
primary biliary cirrhosis when compared to normal liver.

Vimentin did not stain heavily in primary biliary cirrhosis specimens either. There was
no peak florescence of vimentin noted in primary biliary cirrhosis. (Figure 2e.) Red
fluorescence appeared just as weak and perhaps weaker than that of NTPDase2 in
primary biliary cirrhosis. When vimentin and NTPDase2 are viewed together there was
nearly no overlay of green and red fluorescence, and thus an absence of yellow-orange
staining in figure 2c. These data suggest that NTPDase2 in examples of primary biliary
cirrhosis is down regulated in the areas around intra-hepatic bile ducts when compared to
normal liver. Also, vimentin and NTPDase2 did not colocalize in primary biliary
cirrhosis as they did in normal liver suggesting that the portal fibroblast may be down
regulated in this disease.
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When viewed under higher power the distribution of NTPDase2 in primary biliary
cirrhosis reveals a small number of individual cells (labeled SC in figure 2g.) which
fluoresced green wavelengths relatively strongly. There is no vimentin staining within
these cells. They may be hepatic stellate cells. There are also several cells within the
bile duct epithelia which stain moderately above the background for all three cell
markers. (Fl in figures 2d. through 2g.) These infiltrating cells in between the bile duct
cells may represent lymphocytes.

Further evidence that primary biliary cirrhosis has decreased amounts of NTPDase2
comes from our determining the threshold for fluorescence. Primary biliary cirrhosis
unmistakably requires more excitation than normal liver to emit detectable fluorescent
green light. (See table 1) The pin hole required for primary biliary cirrhosis was nearly
twice the gamma length of that required for normal liver. In primary biliary cirrhosis the
voltage of the photomultiplier was significantly higher as determined from higher setting
of the detector gain. The amplifier offset also needed to be appreciably higher to
visualize green fluorescence in primary biliary cirrhosis. Taken together, these
parameters provide strong microscopic evidence that NTPDase2 is down-regulated in
PBC.

Examples of hepatitis C definitely showed a relatively high intensity of fluorescent green
light. NTPDase2 staining when compared to normal liver tissue appears nearly equal.
The fibrotic scar tissue typical hepatocellular fibrosis of hepatitis C stained more heavily

20

21
for NTPDase2 than did the surrounding parenchyma. (Figure 4a.) The areas surrounding
the intrahepatic bile duct, labeled BD in figure 4a showed high staining for NTPDase2.
(Figure 4a.) When viewed under higher power, there was considerable green
fluorescence indicating the presence of NTPDase2 around the bile ducts in
hepatitis C. (Figures 4b.) This fluorescence is plainly stronger than that seen in primary
biliary cirrhosis and perhaps just as strong as that seen in normal liver. Staining for
vimentin showed moderate intensity of red fluorescence immediately adjacent to hepatic
bile ducts. (Figure 4c.) This intensity was not as strong as NTPDase2, and the two stains
did not colocalize. When NTPDase2 and vimentin staining were viewed together, there
was little overlap of the two stains producing only small amounts of yellow-orange
staining. (Data not shown) These data indicate that NTPDase2 expression is virtually
normal in Hepatitis C. The lack of vimentin staining, suggests that NTPDase2 is likely
expressed by cells other than portal fibroblasts. Other data from our laboratory
(unpublished) suggests that these cells may be hepatic stellate cells. While the level of
NTPDase2 fluorescence is equal to that of normal tissue and both are expressed in the
areas around bile ducts, the distributions of NTPDase2 fluorescence are distinct.
NTPDase2 is expressed along the fibrosis of hepatitis C infected liver and not within the
parenchyma. This is unlike normal liver in which staining is limited to the portal tracts
and sinusoidal surfaces of hepatocytes. Moreover, vimentin is decreased and does not
colocalize with NTPDase2 suggesting that either the portal fibroblast is expressing
NTPDase2 and not vimentin, or that the cell is not present in this disease.
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Discussion

The role of extracellular nucleotides in regulating activities in the liver has been
demonstrated previously. (1,3,8,11-16,18,21,22,23,30,31,33) Extracellular nucleotides
induce downstream effects by activating purinergic P2Y receptors. Activation of the
basolateral P2Y receptor of bile duct epithelial cells is potentiated by nucleotide
hydrolysis. NTPDase2 is prime candidate for this activity.

These studies show that the enzyme NTPDase2 is down regulated in primary biliary
cirrhosis. This reduction in NTPDase2 staining is visualized in the regions surrounding
intrahepatic bile ducts as well as in the liver parenchyma. The expression of NTPDase2
as measured by green fluorescence was remarkably decreased in primary biliary cirrhosis.
Confocal immunofluorescence consistently yielded the same result. The threshold
required to visualize green fluorescence was considerably higher for primary biliary
cirrhosis than for normal tissue. Also, blinded observers determined that the intensity of
green fluorescence in primary biliary cirrhosis was nearly one seventh of that observed in
normal tissue. Vimentin, likewise did not show an appreciable staining pattern in
primary biliary cirrhosis. Its expression was conspicuously absent in the regions
surrounding bile ducts.

However, while expression of NTPDase2 was diminished in primary biliary cirrhosis, the
intensity of immunofluorescence was more near normal in hepatitis C infected liver.
Using the same confocal settings as were used for normal liver tissue, hepatitis C emitted
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considerably green immunofluorescence, particularly from the fibrous strains and not
from the parenchyma. Our observational data show that the average observer intensity
for HCV is nearly the same as that for normal tissue. (7.52 vs. 8.40) Also, the two tail pvalue for comparing the average observer intensity between normal liver and HCV was
not statistically significant. (p=0.57) The p-value when comparing normal liver to
primary biliary cirrhosis was p-0.039. Moreover, vimentin, a second marker for portal
fibroblasts was also down regulated in hepatitis C.

Finding that NTPDase2 is down-regulated in examples of primary biliary cirrhosis is in
agreement with our hypothesis. Whether this is a primary result of the pathology of
primary biliary cirrhosis or part of the etiology of the disease is unknown. Further studies
involving other cholangiopathies will be necessary to draw conclusions about the fate of
NTPDase2 in such disease states. In the future studies involving primary sclerosing
cholangitis, cystic fibrosis, and biliary fibrosis secondary to hepatic tumor involvement
would prove useful in determining how NTPDase2 is effected in these cholangiopathies.

While we hypothesized that NTPDase2 would be decreased in primary biliary cirrhosis,
there was no anticipation that vimentin expression would also be decreased. The finding
that vimentin expression is also down regulated raises several questions. Is the portal
fibroblast present in primary biliary cirrhosis? It may be that portal fibroblasts undergo
apoptosis in this disease. If indeed portal fibroblasts prevent basolateral purinergic
receptor activation via NTPDase2 hydrolysis, in the case of biliary stasis there may be a
signal(s) which causes not simply the down regulation of NTPDase2, but actually for
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destruction of the cell. Apoptosis is also a possibility given that primary biliary cirrhosis
and primary is an autoimmune disorder.

Infiltration of inflammatory cells and release of cytokines and inflammatory mediators
may be involved in the destruction of portal fibroblasts. Alternatively there may be an
alteration in gene expression. The portal fibroblast may be present, yet NTPDase2 and
vimentin are both down regulated in primary biliary cirrhosis as a result of inflammatory
mediators. It is interesting to note that both NTPDase2 and vimentin expression are
down-regulated not only in primary biliary cirrhosis but also in hepatitis C. Biliary stasis
may generally cause apoptosis of portal fibroblasts whether due to hepatitis C or primary
biliary cirrhosis. Or perhaps biliary stasis leads to an alteration in gene expression. The
idea of inflammatory mediators playing a role is supported by the fact that bile duct
epithelia secrete TGF-beta2 and portal fibroblasts express TGF-beta receptors
(unpublished data). This signaling pathway may be important in portal fibroblast
function in normal and diseased states.

The figures above also show fluorescence of a particular entity (labeled Fl in Figures 3d.3g. and labeled SC in Figures 4b.-4d.) which possesses NTPDase2, vimentin, and actin.
These entities were noted to be invading the bile duct epithelium of in both primary
biliary cirrhosis and hepatocellular fibrosis. It is conceivable that those entities which
fluoresced all three colors were lymphocytes. It is entirely possible that the immune
system plays a major role in the fate of portal fibroblasts in both primary biliary cirrhosis
and hepatitis C.

24

25
The singular areas of NTPDase2 fluorescence noted in PBC (SC in Figure 2g.) may be
hepatic stellate cells. Other evidence in our laboratory (unpublished) suggests that the
hepatic stellate cell expressed NTPDase2 in disease states. It may in fact be the case that
portal fibroblasts are replaced by hepatic stellate cells in abnormal liver. One possible
way for determining this may be to look for makers specific to hepatic stellate cells.
Another approach is to induce cholangiopathy in a rat model by surgically ligating the
common bile duct, extracting the liver and then looking for evidence of loss of portal
fibroblasts and or increase in hepatic stellate cells. Methods for the isolation of these
cells from whole liver and cell culture have been worked out. (6) Also available are
molecular biology techniques for assessing the presence of RNA or proteins specific to
our cells of interest.(4)

Hepatitis C is not an autoimmune disorder, however, the tissue destruction caused by this
virus undoubtedly leads to the recruitment of a significant number of several immune cell
types. CD8+ T-cells may mediate direct destruction of portal fibroblasts infected with
the virus.

Our studies of normal tissue were consistent with previous data showing the presence of
NTPDase2 and vimentin in the portal areas. However, the expression of NTPDase2 in
the sinusoids of normal tissue is a new finding. It is that more than one ecto-nucleotidase
is present in the canalicular membrane of human hepatocytes. (26-28) Our experiments,
however, clearly indicate the presence of NTPDase2, or some other protein with high
affinity for our antibody, along the sinusoidal surface. We did not appreciate any staining
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along the canalicular surface. It ha s been suggested that the canalicular ectonucleotidases are involved hydrolyzing nucleotides in bile for the purpose of re- uptake
and provision of purines for tissues which lack de novo synthesis. (26) The role of this
potential sinusoidal NTPDase2 and its down regulation in diseased liver is unclear.

We have shown that NTPDase2 is specifically down regulated in primary biliary
cirrhosis. Moreover, this is the first demonstration that a critical protein in nucleotide
signaling is selectively down-regulated in human liver disease. Further studies will
determine whether NTPDase2 is important in the pathogenesis of primary biliary
cirrhosis and other cholangiopathies.
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